Primary liver cancer
Conditions
Interventions
Nalbuphine group:4h after surgery, nalbuphine 0.2mg/Kg was mixed with 100ml normal saline, 40-50 drops/min, TID (8h/ time), for 72h.
Pentazocine group:4h after the operation, the patient was given 30mg pentazocin mixed with 100ml normal saline, 40-50 drops/min, Bid, for 72h.
flurbiprofen axetil group:Flurbiprofen ester (100mg for analgesia) was given 4h after surgery and mixed with 100ml normal saline, 40-50 drops/min, Bid, for 72h.
Nalbuphine and flurbiprofen axetil group:4h after surgery, flurbiprofen ester was given 50mg for analgesia, supplemented with 100ml normal saline, 40-50 drops/min, Bid, and nalbuphine 0.1mg/Kg, supple
pentazocine and flurbiprofen axetil group:4h after surgery, flurbiprofen ester was given 50mg for analgesia mixed with 100ml normal saline intravenous drip, 40-50 drops/min, Bid, and tetazocine 15mg m
Sponsors
Tongji Hospital,Tongji Medical College of Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients who are planning to undergo laparoscopic liver resection; 2. ASA I-III ; 3. Aged = 18 years, voluntarily sign an informed consent form; 4. Body weight 40-90 kg.
Exclusion criteria
Exclusion criteria: 1. People who are allergic to nalbuphine hydrochloride or its components, patients with a history of opioid allergy; 2. History of neurological diseases; 3. History of chronic pain; 4. Drug addiction and alcoholism; 5. History of long-term use of opioids; 6. Patients with coronary heart disease, bronchial asthma, severe hypertension, severe blood system dysfunction, liver and kidney function, and electrolyte abnormalities; 7. Those who have poor compliance and cannot cooperate with surgery; 8. Those who have participated in clinical trials of other drugs in the past 4 weeks; 9. Accompanied by other conditions, the investigator believes that it is not suitable for selected patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS pain score;Postoperative adverse reactions (PONV); | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory factors; | — |
Countries
China
Contacts
Public ContactZhang Lei
Outcome results
None listed